Skip to main content

Peer Review reports

From: Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial

Original Submission
6 Apr 2023 Submitted Original manuscript
27 Apr 2023 Reviewed Reviewer Report
4 May 2023 Reviewed Reviewer Report
5 May 2023 Reviewed Reviewer Report - Siquan Wang
5 Jun 2023 Author responded Author comments - Chongyang Deng
Resubmission - Version 2
5 Jun 2023 Submitted Manuscript version 2
9 Jun 2023 Reviewed Reviewer Report - Siquan Wang
13 Jun 2023 Reviewed Reviewer Report
24 Jun 2023 Reviewed Reviewer Report
29 Jun 2023 Author responded Author comments - Chongyang Deng
Resubmission - Version 3
29 Jun 2023 Submitted Manuscript version 3
13 Jul 2023 Author responded Author comments - Mingtong Xu
Resubmission - Version 4
13 Jul 2023 Submitted Manuscript version 4
7 Aug 2023 Reviewed Reviewer Report
11 Aug 2023 Author responded Author comments - Mingtong Xu
Resubmission - Version 5
11 Aug 2023 Submitted Manuscript version 5
6 Sep 2023 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
21 Sep 2023 Editorially accepted
9 Oct 2023 Article published 10.1186/s12916-023-03089-x

You can find further information about peer review here.

Back to article page